Top Markets
#1 Wrapped One Wrapped One +14,737.38%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +2,972.21%
#3 DeFi Kingdoms DeFi Kingdoms +1,091.68%
#4 Black Phoenix Black Phoenix +336.08%
#5 aPriori aPriori +112.62%
#6 Bedrock Bedrock +74.62%
#7 Cysic Cysic +47.27%
#8 Prom Prom +41.40%
#9 Playnance Playnance +34.98%
#10 COTI COTI +31.11%
Coin of the day
Wrapped One Wrapped One
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Pharnext S.A. Pharnext S.A.

Pharnext S.A.

ALPHA
Kedudukan dalam Saham #42432
Based in France, Pharnext SA is a clinical-stage biopharmaceutical firm... Based in France, Pharnext SA is a clinical-stage biopharmaceutical firm dedicated to creating treatments for a range of neurodegenerative disorders, encompassing both rare (orphan) and common forms. Its pipeline features SYNGILITY, which has advanced through Phase III trials for Charcot-Marie-Tooth disease type 1A (CMT1A). Additionally, PXT864 has concluded Phase II clinical studies for Alzheimer's disease, and is also being explored for its potential in Parkinson's disease and amyotrophic lateral sclerosis (ALS). Pharnext also innovates with PLEOTHERAPY, a proprietary platform that harnesses big genetic data and artificial intelligence. In a collaborative effort, the company holds an agreement with the University Hospital Institute Mediterranee Infection to assess existing pharmaceuticals for their potential application against the COVID-19 virus. The organization was established in 2007, with its main offices located in Issy-Les-Moulineaux, France.
Harga Saham
$0.00023723
Disegerakkan terakhir: 2024-08-26
Modal Pasaran
$1.41K
Perubahan (1 hari)
111.67%
Perubahan (1 tahun)
0.00%
Negara
FR
Perdagangan Pharnext S.A. (ALPHA)

Kategori

Healthcare
Pendapatan untuk Pharnext S.A. (ALPHA)
Pendapatan pada Dec 2023 TTM: $-31.69M
Menurut laporan kewangan terkini Pharnext S.A., pendapatan semasa syarikat ialah $-31.69M. Pada tahun 2022, syarikat memperoleh pendapatan sebanyak $-43.29M, penurunan berbanding pendapatan pada tahun 2021 yang berjumlah $-38.48M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Pharnext S.A. dari 2013 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
2026 (TTM) $-31.69M 1.28%
2023 $-31.29M -27.73%
2022 $-43.29M 12.50%
2021 $-38.48M 30.75%
2020 $-29.43M -0.92%
2019 $-29.70M 21.26%
2018 $-24.50M -15.52%
2017 $-29.00M 29.32%
2016 $-22.42M 87.83%
2015 $-11.94M -8.06%
2014 $-12.98M 1.29%
2013 $-12.82M 0.00%
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -16,747.05%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -6,256.06%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -9,585.74%
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR